- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.03. | Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure | ||
| 19.03. | Pfizer adds to Seagen scrap heap with another early cancer candidate cull | ||
| 19.03. | Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector | ||
| 19.03. | Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals | ||
| 18.03. | Rare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and Congress | ||
| 18.03. | Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome | ||
| 18.03. | Crossbow hits $77M series B round to bankroll quiver of T-Bolts | ||
| 17.03. | Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for' | ||
| 17.03. | J&J changes New York state of mind, closing JLABS site after 8 years | ||
| 17.03. | Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30% | ||
| 17.03. | FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings | ||
| 17.03. | Pfizer's hotly tipped breast cancer prospect delivers phase 2 win | ||
| 16.03. | Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development | ||
| 16.03. | Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years | ||
| 16.03. | Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet | ||
| 13.03. | Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient | ||
| 13.03. | Inovio trims team as trouble brews at FDA for rare disease candidate | ||
| 13.03. | Immutep's phase 3 failure for immunotherapy surprises analysts, sinks stock | ||
| 12.03. | Stop Asking for an AI strategy: 3 questions clinical leaders should ask instead | ||
| 12.03. | Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out | ||
| 12.03. | Vistagen lays off 20% of staff to tighten focus on struggling social anxiety candidate | ||
| 12.03. | Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win | ||
| 12.03. | Small molecules are 'resurgent' in orphan drug R&D: Evaluate | ||
| 12.03. | BridgeBio's muscle weakness data impress ahead of FDA filing | ||
| 12.03. | Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.